Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial
L. Davidescu (Oradea, Romania), P. Chanez (Marseille, France), G. Ursol (Kropyvnytskyi, Ukraine), O. Korzh (Kharkiv, Ukraine), V. Deshmukh (Nagpur, India), L. Kuryk (Kiev, Ukraine), N. Monja-Marie (Brandfort, South Africa), O. Godlevska (Kharkiv, Ukraine), G. Devouassoux (Lyon, France), E. Khodosh (Kharkiv, Ukraine), E. Israel (Boston, United States of America), C. Mansfield (Paris, France), O. Hermine (Paris, France)
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Session: ALERT: Asthma in adults and children
Session type: Clinical trials session
Number: 4612
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Davidescu (Oradea, Romania), P. Chanez (Marseille, France), G. Ursol (Kropyvnytskyi, Ukraine), O. Korzh (Kharkiv, Ukraine), V. Deshmukh (Nagpur, India), L. Kuryk (Kiev, Ukraine), N. Monja-Marie (Brandfort, South Africa), O. Godlevska (Kharkiv, Ukraine), G. Devouassoux (Lyon, France), E. Khodosh (Kharkiv, Ukraine), E. Israel (Boston, United States of America), C. Mansfield (Paris, France), O. Hermine (Paris, France). Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial. 4612
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Late Breaking Abstract - CPAP treatment in the very elderly with Ostructive Sleep Apnea. Pooled results from two multicenter randomized controlled trials Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19 Year: 2021
Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010
Late Breaking Abstract - Supplementation of iron in pulmonary hypertension (SIPHON): results from a randomised controlled crossover trial Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities Year: 2019
Late Breaking Abstract - Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma. Source: Virtual Congress 2021 – Emerging evidence on sub-acute and long COVID-19 Year: 2021
Late Breaking Abstract - Telerehabilitation compared to centre-based pulmonary rehabilitation: a randomised controlled equivalence trial. Source: Virtual Congress 2020 – ALERT: Ventilation and rehabilitation Year: 2020
Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Late Breaking Abstract - Effect on asthma control using a novel digital self-management system: a physician blinded randomised controlled cross-over pilot trial Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018